Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study

Authors: Dupuis, Jehan ^*, Bachy, Emmanuel, Morschhauser, Franck, Cartron, Guillaume, Fukuhara, Noriko, Daguindau, Nicolas, Casasnovas, René-Olivier, Snauwaert, Sylvia, Gressin, Remy, Fox, Christopher P, d’Amore, Francesco Annibale, Staber, Philipp B, Tournilhac, Olivier, Bouabdallah, Krimo, Thieblemont, Catherine, André, Marc, Rai, Shinya, Ennishi, Daisuke, Gkasiamis, Argyrios, Nishio, Mitsufumi, Fornecker, Luc-Matthieu, Delfau-Larue, Marie-Helene, Sako, Nouhoum, Mule, Sebastien, de Leval, Laurence, Gaulard, Philippe, Tsukasaki, Kunihiro, Lemonnier, François

Source: In The Lancet Haematology June 2024 11(6):e406-e414

Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors

Authors: Panse, Jens^1,2 (AUTHOR) jpanse@ukaachen.de, Daguindau, Nicolas³ (AUTHOR), Okuyama, Sonia⁴ (AUTHOR), Peffault de Latour, Régis⁵ (AUTHOR), Schafhausen, Philippe⁶ (AUTHOR), Straetmans, Nicole⁷ (AUTHOR), Al-Adhami, Mohammed⁸ (AUTHOR), Persson, Emmelie⁹ (AUTHOR), Wong, Raymond Siu Ming¹⁰ (AUTHOR)

Source: PLoS ONE. 7/29/2024, Vol. 19 Issue 7, p1-20. 20p.

Subject Terms: *PAROXYSMAL hemoglobinuria, *COMPLEMENT inhibition, *FATIGUE (Physiology), *HEMOGLOBINS, *ECULIZUMAB, *FETAL hemoglobin, *ATRIAL flutter

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

Authors: Aubrais, Raphaelle, Bouabdallah, Krimo ^∗, Chartier, Loic, Herbaux, Charles, Banos, Anne, Brice, Pauline, Sibon, David, Schiano, Jean Marc, Cluzeau, Thomas, Laribi, Kamel, Le Calloch, Ronan, Bellal, Mathieu, Delapierre, Baptiste, Daguindau, Nicolas, Amorim, Sandy, Agbetiafa, Kossi, Chauchet, Adrien, Besson, Caroline, Durot, Eric, Bonnet, Christophe, Fouillet, Ludovic, Bijou, Fontanet, Tournilhac, Olivier, Gaulard, Philippe, Parrens, Marie-Cécile, Damaj, Gandhi

Source: In Blood Advances 10 October 2023 7(19):5733-5742

Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group

Authors: Le Gouill, Steven ^*, Beldi-Ferchiou, Asma ^*, Alcantara, Marion ^*, Cacheux, Victoria, Safar, Violaine, Burroni, Barbara, Guidez, Stéphanie, Gastinne, Thomas, Canioni, Danielle, Thieblemont, Catherine, Maisonneuve, Hervé, Bodet-Milin, Caroline, Houot, Roch, Oberic, Lucie, Bouabdallah, Krimo, Bescond, Charles, Damaj, Ghandi, Jaccard, Arnaud, Daguindau, Nicolas, Moreau, Anne, Tilly, Hervé, Ribrag, Vincent, Delfau-Larue, Marie-Hélène, Hermine, Olivier, Macintyre, Elizabeth

Source: In The Lancet Haematology November 2020 7(11):e798-e807

MDS-112 Normalization of Hematologic and Health-Related Quality of Life Markers in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Pegcetacoplan and Baseline Hemoglobin at or Above 10 g/dL

Authors: Desai, Dharmik ¹, Panse, Jens ², Daguindau, Nicolas ³, Okuyama, Sonia ⁴, de Latour, Régis Peffault ⁵, Schafhausen, Philippe ⁶, Straetmans, Nicole ⁷, Al-Adhami, Mohammed ¹, Ajayi, Temitayo ¹, Persson, Emmelie ⁸, Yeh, Michael ¹, Wong, Raymond ⁹

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S305-S305

The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study

Authors: Sibon, David ^*, Lamant, Laurence ^*, Vergé, Véronique ^*, Ysebaert, Loic ^*, Thieblemont, Catherine, Bouabdallah, Krimo ^*, Dupuis, Jehan ^*, Gressin, Rémy ^*, Bachy, Emmanuel ^*, Guillermin, Yann ^*, Daguindau, Nicolas ^*, Syrykh, Charlotte ^*, Sylvain, Choquet ^*, Feugier, Pierre ^*, Delette, Caroline ^*, Casasnovas, Olivier ^*, Ochmann, Marlene ^*, Le Calloch, Ronan ^*, Gyan, Emmanuel, Tilly, Herve, Damaj, Gandhi Laurent, Tournilhac, Olivier ^*

Source: In Blood 15 November 2022 140 Supplement 1:3680-3682

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Authors: Tournilhac, Olivier ^*, Lecolant, Solene ^*, Hacini, Maya ^*, Bouabdallah, Krimo ^*, Bailly, Sebastien ^*, Laribi, Kamel ^*, Belmondo, Thibaut ^*, Maerevoet, Marie ^*, Ysebaert, Loic ^*, Guidez, Stéphanie ^*, Le Gouill, Steven, Bonnet, Christophe ^*, Andre, Marc ^*, Dupuis, Jehan ^*, Thieblemont, Catherine, Bachy, Emmanuel ^*, Daguindau, Nicolas ^*, Morschhauser, Franck ^*, Tricot, Sabine ^*, Feugier, Pierre ^*, Banos, Anne ^*, Lamy, Thierry ^*, Chauchet, Adrien ^*, Gyan, Emmanuel, Cartron, Guillaume ^*, Farhat, Hassan ^*, Camus, Vincent ^*, Drenou, Bernard ^*, Zerazhi, Hacene ^*, Sibon, David ^*, Nicolas-Virelizier, Emmanuelle ^*, Delette, Caroline ^*, Snauwaert, Sylvia ^*, Straetmans, Nicole, Delarue, Richard, Parrens, Marie ^*, Griolet, Samuel ^*, Gaulard, Philippe ^*, Delfau-Larue, Marie-Helene ^*, De Leval, Laurence, Damaj, Gandhi Laurent ^*

Source: In Blood 15 November 2022 140 Supplement 1:2302-2305

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study

Authors: Dupuis, Jehan ^*, Tsukasaki, Kunihiro, Bachy, Emmanuel ^*, Morschhauser, Franck ^*, Cartron, Guillaume ^*, Fukuhara, Noriko, Daguindau, Nicolas ^*, Casasnovas, René-Olivier ^*, Snauwaert, Sylvia ^*, Gressin, Rémy ^*, Fox, Christopher P. ^*, d'Amore, Francesco Annibale, Staber, Philipp B., Gkasiamis, Argyrios, Nishio, Mitsufumi, Fornecker, Luc-Matthieu ^*, Delfau, Marie-Helene ^*, Sako, Nouhoum ^*, Mule, Sebastien ^*, De Leval, Laurence, Gaulard, Philippe ^*, Lemonnier, Francois ^*

Source: In Blood 15 November 2022 140 Supplement 1:2310-2312

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study.

Authors: Cartron, Guillaume, Bachy, Emmanuel, Tilly, Hervé, Daguindau, Nicolas, Pica, Gian-Matteo, Bijou, Fontanet, Mounier, Christiane, Clavert, Aline, Damaj, Gandhi Laurent, Slama, Borhane, Casasnovas, Olivier, Houot, Roch, Bouabdallah, Krimo, Sibon, David, Fitoussi, Olivier, Morineau, Nadine, Herbaux, Charles, Gastinne, Thomas, Fornecker, Luc-Matthieu, Haioun, Corinne

Source: Journal of Clinical Oncology; 7/1/2023, Vol. 41 Issue 19, p3523-3533, 11p

Immune constitution monitoring after PBMC transplantation in complete DiGeorge syndrome: An eight-year follow-up

Authors: Daguindau, Nicolas, Decot, Véronique, Nzietchueng, Rosine, Ferrand, Christophe, Picard, Capucine, Latger-Cannard, Véronique, Gregoire, Marie José, Beri, Mylène, Salmon, Alexandra, Stoltz, Jean François, Bordigoni, Pierre, Bensoussan, Danièle

Source: In Clinical Immunology 2008 128(2):164-171

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Authors: Claudel, Alexis, Cottereau, Anne Ségolène, Bachy, Emmanuel, Feugier, Pierre, Casasnovas, Rene-Olivier, Haioun, Corinne, Tilly, Herve, Daguindau, Nicolas, Cartron, Guillaume, Nicolas Virelizier, Emmanuelle, Brice, Pauline, Tessoulin, Benoit, Fruchart, Christophe, Glaisner, Sylvie, Delmer, Alain Jacques, Fleck, Emmanuel, Pica, Gian Matteo, Zerazhi, Hacene, Guidez, Stephanie, Cheminant, Morgane, Xerri, Luc, Vercellino, Laetitia, Chartier, Loïc, Gomes, Lucie, Viailly, Pierre-Julien, Delfau, Marie-Helene, Morschhauser, Franck

Source: In Blood 2 November 2023 142 Supplement 1:170-170

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Authors: Aurran-Schleinitz, Therese, Mulligan, Stephen P, Letestu, Remi, Bene, Marie Christine, Cull, Gavin, Vilque, Jean Pierre, Tam, Constantine S., De Guibert, Sophie, Harrup, Rosemary Anne, Drenou, Bernard, Grigg, Andrew P, Voillat, Laurent, Butcher, Belinda E, Dartigeas, Caroline, Eek, Richard, Daguindau, Nicolas, Forsyth, Cecily, Tiab, Mourad, Smith, Delaine, Curnow, Jennifer, Leblond, Veronique, Larsen, Stephen Robert, Cymbalista, Florence, Gottlieb, David

Source: In Blood 2 November 2023 142 Supplement 1:4641-4641

Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

Authors: Ribrag, Vincent, Safar, Violaine, Kluin-Nelemans, Hanneke, Oberic, Lucie, Feugier, Pierre, Casasnovas, Olivier, Thieblemont, Catherine, Daguindau, Nicolas, Damaj, Gandhi Laurent, Hoster, Eva, Fischer von Weikersthal, Ludwig, Hänel, Mathias, Andre, Marc, Da Silva, Maria Gomes, Niebla, Ana Marín, Taszner, Michal, Walewski, Jan, Boersma, Rinske, Delfau-Larue, Marie-Helene, Le Gouill, Steven, Dreyling, Martin

Source: In Blood 2 November 2023 142 Supplement 1:979-979

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.

Authors: Morschhauser, Franck, Nastoupil, Loretta, Feugier, Pierre, Schiano de Colella, Jean-Marc, Tilly, Hervé, Palomba, Maria Lia, Bachy, Emmanuel, Fruchart, Christophe, Libby, Edward N., Casasnovas, Rene-Olivier, Flinn, Ian W., Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L., Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Le Gouill, Steven, Daguindau, Nicolas

Source: Journal of Clinical Oncology; 10/1/2022, Vol. 40 Issue 28, p3239-3245, 7p

S238: CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY.

Authors: Loyaux, Romain, Sako, Nouhoum, Quang, Violaine Tran, Bachy, Emmanuel, Morschhauser, Franck, Cartron, Guillaume, Gressin, Remy, Daguindau, Nicolas, Le Gouill, Steven, Robe, Cyrielle, Boudali, Elisa, Delfau‐Larue, Marie‐Helene, Dupuis, Jehan, De Leval, Laurence, Gaulard, Philippe, Lemonnier, Francois, Sloma, Ivan

Source: HemaSphere; 2023 Supplement 3, Vol. 7, p1-3, 3p

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Authors: Morschhauser, Franck, Nastoupil, Loretta, Feugier, Pierre, Schiano De Colella, Jean Marc, Tilly, Hervé, Palomba, M. Lia, Bachy, Emmanuel, Fruchart, Christophe, Libby, Edward, Casasnovas, Rene-Olivier, Flinn, Ian W., Haioun, Corinne, Maisonneuve, Herve, Ysebaert, Loic, Bartlett, Nancy L., Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Le Gouill, Steven, Daguindau, Nicolas, Delwail, Vincent, Pica, Gian-Matteo, Martin Garcia-Sancho, Alejandro, Lopez-Guillermo, Armando, Larouche, Jean-Francois, Ando, Kiyoshi, Maria, Gomes da Silva, André, Marc, Wu, Ka Lung, Sehn, Laurie H., Izutsu, Koji, Cartron, Guillaume, Gkasiamis, Argyrios, Crowe, Russell, Xerri, Luc, Fowler, Nathan H., Salles, Gilles

Source: In Blood 23 November 2021 138 Supplement 1:2417-2417

Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter

Authors: Panse, Jens, Daguindau, Nicolas, Okuyama Sasaki, Sonia, Peffault De Latour, Regis, Schafhausen, Philippe, Straetmans, Nicole, Al-Adhami, Mohammed, Ajayi, Temitayo, Chen, Crystal, Yeh, Michael, Wong, Raymond S

Source: In Blood 23 November 2021 138 Supplement 1:2194-2194

Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study

Authors: Bouabdallah, Krimo, Aubrais, Raphaëlle, Chartier, Loïc, Herbaux, Charles, Banos, Anne, Brice, Pauline, Ochmann, Marlene, Sibon, David, Schiano De Colella, Jean Marc, Cluzeau, Thomas, Laribi, Kamel, Le Calloch, Ronan, Bellal, Mathieu, Daguindau, Nicolas, Amorim, Sandy, Agbetiafa, Kossi, Chauchet, Adrien, Hammami, Marwa, Durot, Eric, Bonnet, Christophe, Robles, Margot, Fouillet, Ludovic, Bijou, Fontanet, Tournilhac, Olivier, Gaulard, Philippe, Parrens, Marie, Milpied, Noel-Jean, Damaj, Gandhi Laurent

Source: In Blood 23 November 2021 138 Supplement 1:620-620

Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial

Authors: Ribrag, Vincent, Safar, Violaine, Kluin-Nelemans, Hanneke, Oberic, Lucie, Feugier, Pierre, Casasnovas, Olivier, Thieblemont, Catherine, Daguindau, Nicolas, Damaj, Gandhi Laurent, Klapper, Wolfram, Hoster, Eva, Fischer von Weikersthal, Ludwig, Haenel, Mathias, André, Marc, Gomes da Silva, Maria, Carcinero, Fernando, Marin-Niebla, Ana, Taszner, Michal, Walewski, Jan, Boersma, Rinske, Houtenbos, Ilse, Delfau-Larue, Marie-Helene, Le Gouill, Steven, Dreyling, Martin H.

Source: In Blood 23 November 2021 138 Supplement 1:379-379

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”

Authors: Tournilhac, Olivier ^*, Hacini, Maya ^*, Bouabdallah, Kamal ^*, Laribi, Kamel ^*, Maerevoet, Marie ^*, Ysebaert, Loic ^*, Guidez, Stephanie ^*, Le Gouill, Steven, André, Marc ^*, Dupuis, Jehan ^*, Thieblemont, Catherine, Bachy, Emmanuel ^*, Daguindau, Nicolas ^*, Morschhauser, Franck ^*, Tricot, Sabine ^*, Feugier, Pierre ^*, Banos, Anne ^*, Lamy De La Chapelle, Thierry ^*, Chauchet, Adrien ^*, Gyan, Emmanuel, Cartron, Guillaume ^*, Farhat, Hassan ^*, Camus, Vincent ^*, Drenou, Bernard ^*, Zerazhi, Hacene ^*, Sibon, David ^*, Nicolas-Virelizier, Emmanuelle ^*, Delette, Caroline ^*, Snauwaert, Sylvia ^*, Straetmans, Nicole, Delarue, Richard, Parrens, Marie ^*, Bossard, Céline ^*, De Leval, Laurence, Gaulard, Philippe ^*, Damaj, Gandhi Laurent

Source: In Blood 5 November 2020 136 Supplement 1:15-16